## Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4

Amphastar P Form 4 July 07, 2017	harmaceuticals, 7	Inc.									
<b>FORM</b> Check thi if no long subject to	is box	Washington, D.C. 20549									
Section 1 Form 4 or Form 5 obligation may cont <i>See</i> Instru 1(b).	5. <b>SECURITIES</b> Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								Estimated average burden hours per response 0.5		
1. Name and Address of Reporting Person * Shandell Jason B.2. Iss Symbol				- Name <b>and</b> star Pharn			-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
				f Earliest Tr Day/Year) 017	ansaction			_X_ Director 10% Owner _X_ Officer (give title Other (specify below) Delow) President and General Counsel			
				endment, Date Original onth/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> <li>Person</li> </ul>			
CUCAMON (City)	IGA, CA 91730 (State)	(Zip)	Tabl	o I Non D	orivotivo	Soour	itios Aca	uired Disposed of	or Bonoficial	ly Ownod	
	2. Transaction Da (Month/Day/Year	te 2A. Deer ) Executio any	ned		4. Securi on(A) or Di (Instr. 3,	ties Ao spose	cquired d of (D)	uired, Disposed of 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		7. Nature of	
Common Stock	07/05/2017			F	3,394 (1)	D	\$ 17.95	235,493 <u>(2)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amor Unde Secur	le and unt of rlying tities (. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owno Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address		Relationships						
		Director	10% Owner	Officer	Other			
Shandell Jason B. C/O AMPHASTAR PHARMACEUTICAL 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	LS, INC.	X		President and General Counsel				
Signatures								
/s/ Ken Stupak, by power of attorney	07/07/201	7						
**Signature of Reporting Person	Date							

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of RSUs.
- (2) Includes 1,199 shares acquired under the Issuer's 2014 Employee Stock Purchase Plan on May 31, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.